CP-346086 (1-100 mg/kg; oral gavage once daily for 2 weeks) reduces plasma total, VLDL, and LDL cholesterol and triglycerides in mice[1].
CP-346086 (25 mg/kg; a single p.o.) results in an almost complete inhibition of Tyloxapol-induced triglyceride accumulation in fasted rats[1].
CP-346086 (0.1-10 mg/kg; a single p.o.) reduces acute plasma triglyceride in mice[1].
| Animal Model: | B6CBAF1J mice[1] |
| Dosage: | 1, 2, 10, 20, 100 mg/kg |
| Administration: | Oral gavage once daily for 2 weeks |
| Result: | Lowered total, VLDL, and LDL cholesterol and triglycerides dose dependently with 23%, 33%, 75%, and 62% reductions at 10 mg/kg/day. |
